Effects of Dexmedetomidine on Inflammatory Cytokines in Patients With Aneurysmal Subarachnoid Hemorrhage
NCT ID: NCT01565590
Last Updated: 2018-02-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
4 participants
INTERVENTIONAL
2012-02-29
2015-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexmedetomidine and Subarachnoid Haemorrhage
NCT01664520
Fight INflammation to Improve Outcome After Aneurysmal Subarachnoid HEmorRhage
NCT05132920
Cerebral Nitrosative/Oxidative Stress in Aneurysmal Subarachnoid Haemorrhage
NCT05686265
High-Dose Deferoxamine in Intracerebral Hemorrhage
NCT01662895
Carbonic Anhydrase Antagonism in Subarachnoid Hemorrhage
NCT02165644
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Propofol
propofol
5-80 mcg/kg/min
Dexmedetomidine
Dexmedetomidine
0.2-1.5 mcg/kg/hr
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexmedetomidine
0.2-1.5 mcg/kg/hr
propofol
5-80 mcg/kg/min
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* World Federation of Neurological Surgeons (WFNS) grade 4-5 (see table below)
* Surgical intervention with clip or coil
* Placement of cerebrospinal fluid drain (lumbar or ventricular)
* Mechanically ventilated at start of infusion
Exclusion Criteria
* Heart failure class III or IV (New York Heart Association)
* Renal failure (RIFLE classification - see table below)
* Liver failure (serum protein \< 3 g/dL and total bilirubin \> 5 mg/dL)
* Known or suspected brain death
* Pregnancy
* Unable to receive dexmedetomidine within 48 hours of injury and 4 hours of surgery
* Allergy to dexmedetomidine
* Prisoners
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Cincinnati
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Shaun Keegan
Clinical Pharmacy Specialist, Critical Care
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospital
Cincinnati, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
11-11-22-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.